Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction

New England Journal of Medicine

Volumn 341, Issue 19, 1999, Pages 1413-1419

  Zijlstra, Felix ^a   Hoorntje, Jan C A ^a   De Boer, Menko Jan ^a   Reiffers, Stoffer ^a   Miedema, Kor ^a   Ottervanger, Jan Paul ^a   Van 'T Hof, Arnoud W J ^a   Suryapranata, Harry ^a  

^a HOSPITAL DE WEEZENLANDEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

STREPTOKINASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; COST BENEFIT ANALYSIS; FEMALE; FIBRINOLYTIC THERAPY; HEART REINFARCTION; HOSPITAL COST; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CAUSE OF DEATH; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HOSPITAL CHARGES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; RECURRENCE; STREPTOKINASE; SURVIVAL ANALYSIS; THROMBOLYTIC THERAPY;

EID: 0033523869     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199911043411901     Document Type: Article

References (34)

1. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
2. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-402.
3. Granger CB, Califf RM, Topol EJ. Thrombolytic therapy for acute myocardial infarction: a review. Drugs 1992;44:293-325. [Erratum, Drugs 1993;45:894.]
4. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993;328:673-9.
5. Zijlstra F, de Boer MJ, Hoorntje JCA, Reiffers S, Reiber JHC, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993;328:680-4.
6. Gibbons RJ, Holmes DR, Reeder GS, Bailey KR, Hopfenspirger MR, Gersh BJ. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med 1993;328:685-91.
7. de Boer MJ, Suryapranata H, Hoorntje JCA, et al. Limitation of infarct size and preservation of left ventricular function after primary coronary angioplasty compared with intravenous streptokinase in acute myocardial infarction. Circulation 1994;90:753-61.
8. de Boer MJ, Reiber JHC, Suryapranata H, van den Brand MJBM, Hoorntje JCA, Zijlstra F. Angiographic findings and catheterization laboratory events in patients with primary coronary angioplasty or streptokinase therapy for acute myocardial infarction. Eur Heart J 1995;16:1347-55.
9. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-22. [Erratum, N Engl J Med 1994;330:516.]
10. Every NR, Parsons LS, Hlatky M, Martin JS, Weaver WD. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. N Engl J Med 1996;335:1253-60.
11. Lange RA, Hillis LD, Grines CL. Should thrombolysis or primary angioplasty be the treatment of choice for acute myocardial infarction? N Engl J Med 1996;335:1311-7.
12. Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 1997;278:2093-8. [Erratum, JAMA 1998;279:1876.]
13. Zijlstra F, Beukema WP, van't Hof AWJ, et al. Randomized comparison of primary coronary angioplasty with thrombolytic therapy in low risk patients with acute myocardial infarction. J Am Coll Cardiol 1997;29:908-12.
14. Zijlstra F, de Boer MJ, Suryapranata H. Treatment of acute myocardial infarction. N Engl J Med 1993;329:432.
15. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Acute myocardial infarction: pre-hospital and in-hospital management. Eur Heart J 1996;17:43-63.
16. Madsen JK, Grande P, Saunamäki K, et al. Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). Circulation 1997;96:748-55.
17. de Boer MJ, van Hout BA, Liem AL, Suryapranata H, Hoorntje JCA, Zijlstra F. A cost-effective analysis of primary coronary angioplasty versus thrombolysis for acute myocardial infarction. Am J Cardiol 1995;76:830-3.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
19. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34: 187-220.
20. Meijer A, Verheugt FWA, Werter CJPS, Lie KI, van der Pol JMJ, van Eenige MJ. Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study: results of the APRICOT Study. Circulation 1993;87:1524-30.
21. Meier B, Ramamurthy S. Plaque sealing by coronary angioplasty. Cathet Cardiovasc Diagn 1995;36:295-7.
22. Califf RM, Harrelson-Woodlief L, Topol EJ. Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials. Circulation 1990;82:1847-53.
23. Norris RM, White HD. Therapeutic trials in coronary thrombosis should measure left ventricular function as primary end-point of treatment. Lancet 1988;1:104-6.
24. Simoons ML, Serruys PW, van den Brand M, et al. Early thrombolysis in acute myocardial infarction: limitation of infarct size and improved survival. J Am Coll Cardiol 1986;7:717-28.
25. Simoons ML, Vos J, Tijssen JGP, et al. Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the interuniversity Cardiology Institute of the Netherlands. J Am Coll Cardiol 1989;14:1609-15.
26. Kloner RA. Coronary angioplasty: a treatment option for left ventricular remodeling after myocardial infarction? J Am Coll Cardiol 1992;20: 314-6.
27. Goldberg RJ. Assessing the population burden from heart failure: need for sentinel population-based surveillance systems. Arch Intern Med 1999; 159:15-7.
28. Bonneux L, Barendregt JJ, Meeter K, Bonsel GJ, van der Maas PJ. Estimating clinical morbidity due to ischemic heart disease and congestive heart failure: the future rise of heart failure. Am J Public Health 1994;84: 20-8.
29. Morgan S, Smith H, Simpson I, et al. Prevalence and clinical characteristics of left ventricular dysfunction among elderly patients in general practice setting: cross sectional survey. BMJ 1999;318:368-72.
30. Mehta RH, Eagle KA. Secondary prevention in acute myocardial infarction. BMJ 1998;316:838-42. [Erratum, BMJ 1998;317:1516.]
31. Campbell NC, Thain J, Deans HG, Ritchie LD, Rawles JM. Secondary prevention in coronary heart disease: baseline survey of provision in general practice. BMJ 1998;316:1430-4.
32. McCormick D, Gurwitz JH, Lessard D, Yarzebski J, Gore JM, Goldberg RJ. Use of aspirin, β-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities for prevention? Arch Intern Med 1999;159:561-7.
33. Suryapranata H, van't Hof AWJ, Hoorntje JCA, de Boer MJ, Zijlstra F. Randomized comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction. Circulation 1998;97: 2502-5.
34. Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998;98:2695-701.